LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe



    www.labinc.ca
    Toronto Stock Exchange Symbol: LAB

    MONTREAL, June 21 /CNW Telbec/ - LAB International Inc. (TSX: LAB,
Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), a drug development company focused
on developing inhalation therapies for pain treatments, today announced that
it has signed a licensing and development agreement with Janssen Pharmaceutica
NV for Fentanyl TAIFUN(R), its fast-acting Fentanyl formulation using the
company's TAIFUN(R) dry powder inhaler, for the treatment of breakthrough
cancer pain.
    The licensing agreement covers the European Union, Eastern Europe,
Russia, the Middle-East and Africa. LAB and Janssen Pharmaceutica will
collaborate to develop the product for the initial indication of breakthrough
cancer pain. Janssen Pharmaceutica NV will be marketing authorization holder
in the territories covered by the agreement and will also be responsible for
developing any additional indications. LAB will manufacture the product for
all territories. The Janssen-Cilag companies will market and distribute the
product. Under the terms of the agreement, LAB will receive a signing fee of
US $10.8 million ((euro) 8.0 million), up to US $33.6 million
((euro) 25.0 million) in development and regulatory milestones as well as
payments of commercial sales milestones. LAB could receive significant royalty
income on sales of the product as well as manufacturing profit.
    "We are extremely pleased to have partnered our lead product, Fentanyl
TAIFUN(R), with the originator of fentanyl that was successfully marketed by
Janssen-Cilag companies as DUROGESIC(R), the Fentanyl transdermal patch. The
company's world class product development and marketing expertise combined
with Fentanyl TAIFUN(R)'s superior formulation and therapeutic profile should
make it an important therapeutic option for many patients.", said Dr. Halvor
Jaeger, Chief Executive Officer of LAB International.
    Janssen Pharmaceutica NV is a Belgium based worldwide pharmaceutical
center of excellence for integrated R&D, production and general services. With
a track record consisting of more than 80 medicines, the company is among the
most innovative in the world and its products are available all over the
globe.
    The Janssen-Cilag companies have a long track record in developing and
marketing treatments for central nervous system disorders, pain management,
oncology, fungal infections and gastrointestinal conditions. Leading products
include Concerta(R) (ADHD), Durogesic(R) (pain management), Eprex(R) (anemia),
Pariet(R) (gastroenterology), Topamax(R) (epilepsy, migraine prevention),
Reminyl(R) (Alzheimer's disease), Risperdal(R) (schizophrenia, bipolar
disorders, disruptive behavior), Risperdal(R) Consta(R) (schizophrenia) and
Velcade (multiple myeloma).

    Conference call information:

    LAB will host a conference call at 2:00 pm, on Thursday June 21, 2007.
Interested parties may also access the conference call by webcast at
www.labinc.ca.
    The telephone numbers to access the conference call are 416-644-3414 or
1-800-732-9303. A replay of the call will be available until Thursday June 28,
2007. The telephone numbers to access the replay are 416-640-1917 and
1-877-289-8525 with code number 21237175#.

    About Breakthrough Pain

    Chronic pain associated with advanced cancer is commonly treated with
opioid analgesics, such as fentanyl. Breakthrough pain episodes are sudden and
intense flares of pain that "break through" a long-acting continuous
treatment, such as a transdermal patch or sustained release oral formulations.
Break-through pain episodes are common in cancer patients, often occurring
several times a day.

    About LAB International

    LAB International is an integrated drug development company focused on
the growing multi-billion dollar inhalation market. Its lead product, for the
treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation
delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its
pipeline also includes therapeutics for asthma, COPD, and growth hormone
deficiencies.
    LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the
symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol
"LD9.F" and on XETRA under the symbol "LD9.DE" with 82.3 million shares
outstanding.

    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of LAB International Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF




For further information:

For further information: Frédéric Dumais, Vice-President, Investor
Relations, (514) 315-3330 ext. 106, Fax: (514) 315-3325, dumaisf@labinc.ca;
www.labinc.ca

Organization Profile

Akela Pharma Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890